Stifel Reiterates Bullish View on Kite Pharma (KITE) Following New Trial News
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/3/2024
- Wall St ends sharply higher, jobs data strengthens case for rate cuts
- U.S. adds fewer jobs than anticipated in April
- Apple shares rise more than 5% premarket after Q2 results top downbeat estimates
- Amgen (AMGN) stock soars on positive obesity drug update, analyst raises PT
- Oil settles down on US jobs data, steepest weekly loss in 3 months
- Midday movers: Apple, Amgen and Block rise; Cloudflare and Expedia fall
- After-hours movers: Apple, Block, Coinbase, Booking and more
- Midday movers: Carvana and Qualcomm rise; DoorDash, Fastly, Zillow fall
- After-hours movers: Qualcomm, Carvana rise; DoorDash, Etsy, Fastly fall
- Midday movers: Amazon, Pfizer, Pinterest rise; AMD, Starbucks, CVS Health fall
Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)
October 6, 2016 8:30 AM EDTFirst patient enrolled in ZUMA-6 study evaluating safety and efficacy of anti-CD19 CAR (KTE-C19) therapy in combination with anti-PD-L1 monoclonal antibody atezolizumab
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentechs anti-PD-L1 cancer immunotherapy. The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma (DLBCL).
PD-L1 expression in DLBCL is associated with... More
